DERMSCAN Report issue

For profit Phase 3
Founded: Lyon France (1990)
Status: Acquired by Eurofins (2018)

Organization Overview

First Clinical Trial
2004
NCT01368224
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dermascan

Active Ingredients

Drugs in Phase 3 Trials (2)

bifidobacterium longum (1 trial)

lactobacillus casei (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypersensitivity (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2